Keßler, T., & Müller-Tidow, C. (2019). Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML). Annals of hematology, 98(6), . https://doi.org/10.1007/s00277-019-03651-9
Chicago-Zitierstil (17. Ausg.)Keßler, Torsten, und Carsten Müller-Tidow. "Phase II Clinical Trial of Pazopanib in Patients with Acute Myeloid Leukemia (AML), Relapsed or Refractory or at Initial Diagnosis Without an Intensive Treatment Option (PazoAML)." Annals of Hematology 98, no. 6 (2019). https://doi.org/10.1007/s00277-019-03651-9.
MLA-Zitierstil (9. Ausg.)Keßler, Torsten, und Carsten Müller-Tidow. "Phase II Clinical Trial of Pazopanib in Patients with Acute Myeloid Leukemia (AML), Relapsed or Refractory or at Initial Diagnosis Without an Intensive Treatment Option (PazoAML)." Annals of Hematology, vol. 98, no. 6, 2019, https://doi.org/10.1007/s00277-019-03651-9.